Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 983-991

  Liu, Miao ^a   Mo, Qin Guo ^a   Wei, Chang Yuan ^a   Qin, Qing Hong ^a   Huang, Zhen ^a   He, Jie ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Platinum; Triple negative breast cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; MITOMYCIN; PACLITAXEL; PROGESTERONE RECEPTOR; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST METASTASIS; CANCER CONTROL; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; HYPERKALEMIA; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

EID: 84872694705     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1093     Document Type: Article

References (17)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
2. Turner N, Tutt A and Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819, 2004.
3. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018, 2008.
4. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
5. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L and FordJM: Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 11: 7, 2011.
6. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153, 2010.
7. Frasci G, D'Aiuto G, Comella P, D'Aiuto M, Di Bonito M, Ruffolo P, et al: Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol 21: 707-716, 2010.
8. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D and StroupDF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900, 1999.
9. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19: 1847-1852, 2008.
10. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, ChungDU and Gornbein J: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116: 4227-4237, 2010.
11. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, et al: Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 21: 961-967, 2010.
12. Koshy N, Quispe D, Shi R, Mansour R and Burton GV: Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19: 246-248, 2010.
13. Chan D, Yeo WL, Tiemsim CM, Wong CI, Chuah B, Soo R, et al: Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs 28: 859-865, 2010.
14. Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, et al: Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124: 1457-1462, 2009.
15. Staudacher L, Cottu PH, Diéras V, Vincent-Salomon A, Guilhaume MN, Escalup L, et al: Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22: 848-856, 2011.
16. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, MejiaJA, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
17. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, et al: Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 107: 1459-1466, 2006.